Ascendia

  MARKET NEWS

Sterling Pharma Solutions Completes Acquisition of API Manufacturing Facility in Ireland
CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for Novel Immunotherapeutic for Type 1 Diabetes
Atavistik Bio Announces Collaboration With Plex Research to Enrich the Informatics Capabilities of its AMPS Platform & Accelerate the Discovery of Novel Small Molecule Therapeutics
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients With Heart Failure With Preserved Ejection Fraction

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Ajinomoto & Exelixis Enter License Agreement to Discover & Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Ajinomoto Co., Inc. recently announced a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of….

Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI

Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI

This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic….

Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Rani Therapeutics Holdings, Inc. recently announced it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar….

Transgene Receives Approval to Start a Phase 1 Trial of  Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Transgene Receives Approval to Start a Phase 1 Trial of  Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 18 – Drug Delivery
Jnuary 25 – Bioavailability